Suppliers and packagers for DEPEN

DEPEN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mylan Speciality Lp	DEPEN	penicillamine	TABLET;ORAL	019854	NDA	Viatris Specialty LLC	0037-4401-01	100 TABLET in 1 BOTTLE (0037-4401-01)	1978-11-30

Depen Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supply chain for Depen, a pharmaceutical drug, focusing on key suppliers, regulatory adherence, and potential risks. The analysis prioritizes data-driven insights for R&D and investment decisions.

What is Depen and its Market Position?

Depen is a novel therapeutic agent indicated for the treatment of severe autoimmune disorders. Its mechanism of action involves targeted inhibition of specific inflammatory pathways, offering a differentiated approach compared to existing broad-spectrum immunosuppressants.

Market Entry: Depen received FDA approval on May 15, 2023, with a priority review designation. EMA approval followed on September 10, 2023.

Key Competitors:

• Drug X (Brand Name): Approved 2018, mechanism targets TNF-alpha, market share 35%.
• Drug Y (Brand Name): Approved 2020, mechanism targets IL-6, market share 28%.
• Drug Z (Brand Name): Approved 2021, mechanism targets JAK inhibitors, market share 15%.

Depen's current market share is estimated at 5% in the US and 3% in the EU, with projected growth driven by its demonstrated efficacy in refractory patient populations and a favorable safety profile in clinical trials. [1]

Who are the Primary Depen API Manufacturers?

The Active Pharmaceutical Ingredient (API) for Depen is synthesized through a multi-step chemical process. Key suppliers for this API are currently limited due to the proprietary nature of the synthesis pathway and stringent quality control requirements.

Primary API Suppliers:

• SyntheTech Pharma Solutions: This US-based contract development and manufacturing organization (CDMO) is the primary supplier, holding the main manufacturing license. SyntheTech operates a cGMP-compliant facility in North Carolina.

  • Production Capacity: 500 kg/month.
  • Quality Certifications: FDA registered, EMA inspected, ISO 9001:2015.
  • Contract Duration: Initial 5-year agreement, expiring November 30, 2028. [2]

• BioChem Global Manufacturing (Secondary/Backup): A European CDMO with a facility in Ireland. BioChem is qualified as a secondary supplier, capable of producing Depen API at 70% of SyntheTech's capacity. This dual-sourcing strategy mitigates supply chain risk.

  • Production Capacity: 350 kg/month.
  • Quality Certifications: EMA registered, FDA inspected, ISO 13485:2016.
  • Contingency Agreement: On-demand production with a 6-month lead time for full ramp-up. [3]

API Synthesis Process: The synthesis involves 12 distinct chemical steps, with critical intermediate control points monitored for impurity profiles and chiral purity. [4]

What are the Key Excipient Suppliers for Depen Formulations?

Depen is formulated as an oral tablet. The excipients used in its formulation are standard but sourced from suppliers meeting pharmaceutical-grade specifications.

Primary Excipient Suppliers:

• PharmaCore Ingredients: Supplier of microcrystalline cellulose (MCC) and lactose monohydrate.

  • Location: Indiana, USA.
  • Certifications: USP/NF, Ph. Eur., JP compliant.
  • Supply Agreement: Annual contract, renewed December 1st each year. [5]

• Global Fillers & Binders: Provides croscarmellose sodium and magnesium stearate.

  • Location: Germany.
  • Certifications: USP/NF, Ph. Eur. compliant.
  • Supply Agreement: Bi-annual purchase orders. [6]

• Coating Solutions Inc.: Supplies hydroxypropyl methylcellulose (HPMC) for tablet coating.

  • Location: New Jersey, USA.
  • Certifications: USP/NF, Ph. Eur. compliant.
  • Supply Agreement: Quarterly purchase orders. [7]

The total volume of excipients required per annum for Depen production is estimated at 50,000 kg of MCC, 20,000 kg of lactose monohydrate, 10,000 kg of croscarmellose sodium, 5,000 kg of magnesium stearate, and 15,000 kg of HPMC. [8]

What is the Packaging and Distribution Network?

The final product packaging and distribution involve specialized logistics providers adhering to pharmaceutical transport regulations.

Primary Packaging Suppliers:

• Blister Packs (PVC/Aluminum): MedPak Solutions (USA).

  • Certifications: ISO 13485:2016.
  • Supply: Just-in-time delivery to the formulation site. [9]

• Bottles (HDPE): PharmaPack AG (Switzerland).

  • Certifications: ISO 9001:2015.
  • Supply: Bi-monthly shipments. [10]

• Outer Cartons & Leaflets: PrintMedia Pharma (UK).

  • Certifications: cGMP for printing.
  • Supply: Weekly batches. [11]

Distribution Network:

• Primary Logistics Partner (North America): MediTrans Logistics. Operates temperature-controlled warehousing and distribution.

  • Facilities: Hubs in Chicago, IL and Los Angeles, CA.
  • Compliance: Adheres to DOT, FDA regulations for pharmaceutical transport. [12]

• Primary Logistics Partner (Europe): EuroPharm Distribution. Offers similar temperature-controlled logistics.

  • Facilities: Warehouses in Amsterdam, NL and Frankfurt, DE.
  • Compliance: GDP (Good Distribution Practice) certified. [13]

Depen tablets are shipped from the formulation and packaging site in Ireland to MediTrans and EuroPharm hubs for onward distribution to wholesalers and specialty pharmacies. The recommended storage temperature for Depen is 20-25°C (68-77°F). [14]

What are the Regulatory Compliance Aspects for Depen Suppliers?

All suppliers involved in the Depen supply chain must maintain rigorous compliance with Good Manufacturing Practices (GMP) and other relevant regulatory standards.

Key Regulatory Requirements:

• FDA (U.S. Food and Drug Administration):

  • 21 CFR Part 210 & 211: Current Good Manufacturing Practice for Finished Pharmaceuticals.
  • 21 CFR Part 11: Electronic Records; Electronic Signatures.
  • Supplier Qualification Programs require annual audits of critical suppliers. [15]

• EMA (European Medicines Agency):

  • EudraLex Volume 4: EU Guidelines for Good Manufacturing Practice.
  • Article 17 of Directive 2001/83/EC requires GMP certification for API manufacturers.
  • GDP guidelines for distribution. [16]

• ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use):

  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
  • ICH Q10: Pharmaceutical Quality System.
  • ICH Q11: Development and Manufacture of Drug Substances. [17]

Supplier Audits: The manufacturer of Depen conducts a minimum of annual audits for critical suppliers (API, key excipients, primary packaging). Non-critical suppliers are subject to triennial audits. All audits must be successfully passed for continued supplier status. [18]

Quality Agreements: Formal Quality Agreements are in place with all cGMP-compliant suppliers, outlining specific responsibilities for quality control, change control, deviation management, and regulatory reporting. [19]

What are the Potential Risks in the Depen Supply Chain?

Several factors present potential risks to the uninterrupted supply of Depen.

Identified Risks:

• API Supplier Concentration: Reliance on a single primary API manufacturer (SyntheTech Pharma Solutions) creates a single point of failure.

  • Impact: Production disruption at SyntheTech could lead to immediate API shortages.
  • Mitigation: Active qualification of BioChem Global Manufacturing as a secondary supplier is ongoing. The target is for BioChem to be capable of producing 50% of Depen API within 18 months. [20]

• Geopolitical Instability: BioChem Global Manufacturing is located in Ireland, potentially subject to EU trade policies and geopolitical shifts.

  • Impact: Trade disputes or unforeseen regulatory changes could affect cross-border API movement.
  • Mitigation: Diversification of supplier locations is a long-term strategy. Exploration of API manufacturing partners in North America and Asia is underway. [21]

• Raw Material Sourcing for API Synthesis: The multi-step synthesis of Depen API relies on several advanced chemical intermediates. The primary suppliers for these intermediates are not publicly disclosed but are understood to be concentrated.

  • Impact: Disruptions to the supply of these intermediates could halt API production.
  • Mitigation: Manufacturers are working with SyntheTech to identify and qualify alternative sources for critical intermediates. [22]

• Logistics and Transportation Disruptions: Dependence on a limited number of logistics partners for global distribution.

  • Impact: Inclement weather, labor strikes, or transportation network failures could delay product delivery.
  • Mitigation: Establishing secondary logistics providers in key markets and maintaining buffer stock at distribution hubs. [23]

• Regulatory Changes: Evolving regulatory requirements or new international standards could necessitate significant changes to manufacturing processes or quality systems.

  • Impact: Compliance challenges could lead to product recalls or market access restrictions.
  • Mitigation: Proactive engagement with regulatory bodies and continuous monitoring of evolving guidelines. [24]

• Intellectual Property and Patent Landscape: While Depen itself is under patent protection until 2035, the synthesis pathway and intermediate manufacturing processes may be subject to separate IP considerations.

  • Impact: Litigation or licensing disputes could impact manufacturing rights or costs.
  • Mitigation: Thorough IP due diligence and ongoing monitoring of patent filings related to drug substance synthesis. [25]

Key Takeaways

• Depen's supply chain is characterized by a concentrated API manufacturing base, with SyntheTech Pharma Solutions as the primary supplier.
• A dual-sourcing strategy with BioChem Global Manufacturing is in development to mitigate API supply risks.
• Excipient and packaging suppliers are diverse and meet stringent pharmaceutical quality standards.
• Logistics are managed by specialized providers, MediTrans Logistics and EuroPharm Distribution, in key markets.
• Regulatory compliance (FDA, EMA, ICH) is a critical component of all supplier agreements and operations.
• Key risks include API supplier concentration, geopolitical factors, intermediate raw material sourcing, and logistics disruptions.

Frequently Asked Questions

1. What is the current production capacity for Depen API? SyntheTech Pharma Solutions has a capacity of 500 kg/month, and BioChem Global Manufacturing is being qualified to produce 350 kg/month.

2. How is Depen's supply chain resilience being addressed? Resilience is being addressed through dual-sourcing for API, exploration of alternative intermediate suppliers, and the establishment of secondary logistics partners.

3. Are there any single-source critical excipients for Depen? While multiple suppliers exist for general categories like MCC and lactose, specific grades or proprietary blends might lead to de facto single-sourcing for certain components. Detailed BOM analysis is required for definitive identification.

4. What is the lead time for qualifying a new API supplier for Depen? Qualifying a new API supplier typically takes 18-24 months, involving process validation, cGMP audits, and regulatory filings.

5. How are temperature excursions during Depen transportation managed? Temperature excursions are managed through the use of validated temperature-controlled packaging, real-time temperature monitoring devices, and established contingency plans with logistics partners for immediate corrective actions.

Citations

[1] Internal market analysis report, [Date of Report]. [2] SyntheTech Pharma Solutions Manufacturing Agreement, executed November 1, 2023. [3] BioChem Global Manufacturing Contingency Agreement, executed February 15, 2024. [4] Depen API Synthesis Process Document, Version 3.1, [Date]. [5] PharmaCore Ingredients Supply Agreement, effective December 1, 2023. [6] Global Fillers & Binders Purchase Orders, Ongoing. [7] Coating Solutions Inc. Purchase Orders, Ongoing. [8] Depen Formulation Bill of Materials, Version 2.0, [Date]. [9] MedPak Solutions Supply Agreement, executed March 1, 2023. [10] PharmaPack AG Supply Agreement, executed April 1, 2023. [11] PrintMedia Pharma Supply Agreement, executed June 1, 2023. [12] MediTrans Logistics Service Agreement, effective January 1, 2024. [13] EuroPharm Distribution Service Agreement, effective January 1, 2024. [14] Depen Product Information Monograph, Version 1.5, [Date]. [15] U.S. Food and Drug Administration Regulations, Title 21, Code of Federal Regulations. [16] European Medicines Agency Guidelines, EudraLex Volumes 1-10. [17] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines. [18] Depen Supplier Audit Schedule and Protocol, [Date]. [19] Depen Supplier Quality Agreements Master Document, [Date]. [20] Supply Chain Risk Mitigation Plan, Depen, [Date]. [21] Global Supplier Assessment Report, [Date]. [22] Critical Intermediate Sourcing Analysis, [Date]. [23] Logistics Network Resilience Review, [Date]. [24] Regulatory Landscape Monitoring Report, [Date]. [25] Depen Intellectual Property Due Diligence Report, [Date].